Anti Wrinkle Injections
How can Toxin injections reduce wrinkles, and where can it be used?
Wrinkle Reduction Treatment treatment involves strategically placing standardised injections of Botulinum Toxin Type A such as Botox® or Azzalure®, into targeted facial muscles.
The judgement of the practitioner in targeting the most appropriate facial muscles can provide dramatic results. The forced relaxation of the muscle can dramatically improve the appearance of forehead lines, frown lines, and crows feet lines around the eyes. It has been the most sought after non-surgical cosmetic treatment for some time.
Botulinum Toxin Type A provides effective treatment for the temporary relief of moderate to severe vertical lines between the brows (glabellar lines). It has also been found to be clinically effective in treating forehead and crows feet lines and is used widely for this purpose within the aesthetics industry. Botox® has a cosmetic license for use in the Glabellar and Crows Feet areas only, with all other use being considered off-license.
Botulinum Toxin Type A works by interrupting the nerves signals to the muscles thereby limiting their movement and reducing their wrinkling action on the skin. It contains tiny amounts of highly purified and sterile Botulinum Toxin protein refined from the bacterium, Clostridium Botulinum. Used in very small doses, the Toxin behaves differently in the skin than it does in the body.
How long will the treatment take to work and how long will it last?
You will start to notice the effects within 3-5 days, although the full effect of your treatment will take 2 weeks, at which time your results will be assessed. Results will vary and are dependent on the severity of your wrinkles, skin laxity, muscle strength, your age, general health as well as environmental influences. Generally you can expect the effects of your first treatment to last for 3-4 months. Following a series of treatments, the re-treatment time may lengthen to up to 5-6 months. Treatments are not recommended before a 3 month time lapse as it is believed this may prompt the body to produce neutralising antibodies, resulting in less effective treatments in the future.
Who can provide treatments?
Botulinum Toxin Type A (i.e. Botox® or Azzalure®) is a prescription only medication (POM) which means a complete, face-to-face, individual consultation and assessment is required before treatment carried out. This prescription can only be provided by a Healthcare Professional (Doctor, Dentist or a trained Independent Nurse Prescriber). The treating practitioner must also be suitably trained and accredited in the administration of Botulinum Toxin and should be adequately insured. We will work with you in order to ensure your suitability for treatment, counsel you on your expectations and offer a clear assessment of treatment options and expected results.
What are the side effects?
may include redness, swelling, bruising, bleeding, or pain at the injection site. Some clients report a slight headache following their first few treatments, which is easily alleviated with Paracetamol. Less frequently, nausea and flu like symptoms have been reported. If there is a drop in the brows a ‘hooded’ effect or heaviness over the eyes may result. Similarly, but more rarely, a drop in the eyelid may occur as a result of product migration, misplacement, overtreatment, or client sensitivity to the Toxin. Again, you can expect any side effects to be temporary.
Who is suitable for treatments?
Treatments are most suitable for those in good health, who would benefit clinically from the wrinkle reducing effects of Botulinum Toxin Type A (i.e. Botox® or Azzalure®) and are between the age of 18 and 65.
Botulinum Toxin Type A is not recommended for women who are pregnant or breastfeeding, those with an active infection or wound in the treatment area, a bleeding disorder, or those with a known sensitivity to any of the Botulinum Toxins.
It is also contraindicated for those with any neuromuscular deficit, myasthenia gravis, Eaton Lambert syndrome, amyotrophic lateral sclerosis and those taking the following medications which may also decrease neuromuscular transmission: aminoglycosides, penicillamine, quinine, and calcium channel blockers.
Botox® is a registered trademark of Allergan Ltd and was licensed in the UK for medical use in 1994. It was licensed in 2006 for aesthetic use under the brand name Vistabel®.
Azzalure® is a registered trademark of Galderma Ltd and was licensed for the temporary relief of glabellar lines in 2008.